Treatment of superficial bladder cancer with intravesical mitomycin C

Analysis of immediate and long-term response in 70 patients

M. S. Soloway

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.

Original languageEnglish
Pages (from-to)1107-1109
Number of pages3
JournalJournal of Urology
Volume134
Issue number6
StatePublished - Dec 1 1985
Externally publishedYes

Fingerprint

Mitomycin
Urinary Bladder Neoplasms
Therapeutics
Neoplasms
Thiotepa
Muscles
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Treatment of superficial bladder cancer with intravesical mitomycin C : Analysis of immediate and long-term response in 70 patients. / Soloway, M. S.

In: Journal of Urology, Vol. 134, No. 6, 01.12.1985, p. 1107-1109.

Research output: Contribution to journalArticle

@article{0398c7e3d4b64e02bbfe715fe28e8900,
title = "Treatment of superficial bladder cancer with intravesical mitomycin C: Analysis of immediate and long-term response in 70 patients",
abstract = "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.",
author = "Soloway, {M. S.}",
year = "1985",
month = "12",
day = "1",
language = "English",
volume = "134",
pages = "1107--1109",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of superficial bladder cancer with intravesical mitomycin C

T2 - Analysis of immediate and long-term response in 70 patients

AU - Soloway, M. S.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.

AB - A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.

UR - http://www.scopus.com/inward/record.url?scp=0022384393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022384393&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 1107

EP - 1109

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -